Cyclops Medtech is a medtech startup based in Bengaluru, India, that makes BalanceEye, an eye-tracking diagnostic device for vertigo and balance disorders used by clinicians.

This Startup Deep Dive explains what Cyclops Medtech does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Cyclops Medtech in Brief

• What it is: Cyclops Medtech is an Indian Vertigo diagnostic devices company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company's flagship product BalanceEye is a non-invasive balance assessment solution that tracks pupil movement to diagnose vertigo and other neuro-vestibular and balance disorders.
• It designs diagnostic and rehabilitation products for neuro-vestibular disorders using eye-tracking, targeting about 20 conditions including vertigo, epilepsy, migraine and concussion.
• Captured images are sent to the cloud and the algorithm's analysis is vetted by a team of clinicians.
• Funding: about USD 1M disclosed (2018) plus undisclosed earlier angel and seed rounds.

Cyclops Medtech Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Cyclops Medtech?

Cyclops Medtech operates in the Vertigo diagnostic devices space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Cyclops Medtech.

• The company's flagship product BalanceEye is a non-invasive balance assessment solution that tracks pupil movement to diagnose vertigo and other neuro-vestibular and balance disorders.
• It designs diagnostic and rehabilitation products for neuro-vestibular disorders using eye-tracking, targeting about 20 conditions including vertigo, epilepsy, migraine and concussion.
• Captured images are sent to the cloud and the algorithm's analysis is vetted by a team of clinicians.
• Product listings also show VNG, VOG, vHIT, dynamic visual acuity, VR-based vestibular rehabilitation and stabilometry offerings.

The Origin Story of Cyclops Medtech

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Niranjan Subbarao, Srinivas Dorasala, Ravi Nayar.
• Founded in 2015 by Niranjan Subbarao, a serial entrepreneur, with Srinivas Dorasala (also called Dr DR Srinivas in some coverage) and Ravi Nayar, described as doctors.
• A pre-seed round for prototype development came from a leading Bengaluru surgeon.
• The team includes doctors, engineers and business professionals; Subbarao is listed as CEO.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Vertigo diagnostic devices sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2015: founded and named a Tech30 company.
• June 2016: undisclosed seed round from CP Bothra of Medreich Pharma (reported).
• 2017: won the NASSCOM Emerge 50 League of 10 award; company claimed 46 paid installations in 26 cities across 3 countries.
• September 2018: USD 1M round led by Unitus Ventures with CP Bothra participating, facilitated by LetsVenture; about 100 installations and 10,000 tests reported.
• 2018 plan: three more neuro-vestibular products and a stroke screening product.

Cyclops Medtech Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported: pre-seed from a Bengaluru surgeon, amount undisclosed.
• Reported: seed from CP Bothra, June 2016, undisclosed.
• Reported: USD 1M early-stage round in September 2018 led by Unitus Ventures with CP Bothra participating (LetsVenture facilitated).
• Listings also name Capria Ventures and Plug and Play Japan as investors, with no amounts.

How Does Cyclops Medtech Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells diagnostic medical device hardware to clinics and hospitals, with a subscription base growing alongside installations.
• Clinicians and technicians are trained free at every site where the device is installed.
• The founder declined to share the device price in 2018 coverage.

The Numbers: Cyclops Medtech Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• About 100 BalanceEye installations across about 50 cities and 10,000 tests, roughly 16 months after launch (2018 reports).
• Company claimed about 62% market share in its segment, with about 60% of installations in non-metro cities and towns (2018, company-stated).
• 2018 target of 1,000 installations over five years (the investor's announcement said 1,500).
• 2021 cap table snapshot: Subbarao held 20.4% and founders collectively about 56.6% as of 31 March 2021 (single aggregator).
• No revenue or profit figures found.

Market Opportunity for Cyclops Medtech

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Targets vertigo and balance disorder diagnosis, with a focus on Tier 2 and Tier 3 Indian cities and other Asian markets (ASEAN).
• About 20 diseases addressed across vertigo, epilepsy, migraine and concussion.

Technology and Product at Cyclops Medtech

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Eye-tracking (video-oculography) based balance assessment in the BalanceEye device with cloud analysis and clinician vetting.

Team and Culture at Cyclops Medtech

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Niranjan Subbarao is CEO and the largest shareholder per a 2021 snapshot.
• A team of doctors, engineers and business professionals (2018).

Cyclops Medtech Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Cyclops Medtech

• Single-product focus on vertigo and balance diagnostics.
• Global vestibular diagnostics vendors are far larger.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Cyclops Medtech Growth Outlook: What to Watch

• In 2018 the company said it planned to scale up production, deepen Tier 2/3 city coverage, enter other Asian markets and develop more products with the new funding.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Cyclops Medtech can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Cyclops Medtech Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Cyclops Medtech

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Cyclops Medtech.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Cyclops Medtech

Studying a company in the Vertigo diagnostic devices space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Cyclops Medtech.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Cyclops Medtech as a Startup

• Customer clarity: Can Cyclops Medtech name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Cyclops Medtech is part of India’s growing Vertigo diagnostic devices ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Cyclops Medtech FAQs: Frequently Asked Questions

What is Cyclops Medtech?

Cyclops Medtech is a medtech startup based in Bengaluru, India, that makes BalanceEye, an eye-tracking diagnostic device for vertigo and balance disorders used by clinicians. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Cyclops Medtech?

Cyclops Medtech was founded by Niranjan Subbarao, Srinivas Dorasala, Ravi Nayar, and the company reports a founding year of 2015.

How much funding has Cyclops Medtech raised?

about USD 1M disclosed (2018) plus undisclosed earlier angel and seed rounds. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Cyclops Medtech make money?

Cyclops Medtech earns revenue from its Vertigo diagnostic devices products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Cyclops Medtech?

Reported rivals include Interacoustics, Natus. See the competitor comparison above for how they differ.

What are the main risks for Cyclops Medtech?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: MedGenome — MedGenome: India’s genomics player with a $47.5M Series E | Equal — Equal raised $10M Series A at a reported $80M valuation. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.